<DOC>
	<DOCNO>NCT00846443</DOCNO>
	<brief_summary>The purpose study determine recommend dose pemetrexed maximum tolerate dose radiotherapy use concurrent pemetrexed/cisplatin/radiotherapy patient local advance non-small cell lung cancer .</brief_summary>
	<brief_title>Study Concurrent Pemetrexed , Cisplatin Radiotherapy Local Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>This study conduct explore feasibility concurrent chemoradiation therapy pemetrexed , cisplatin radiotherapy unresectable local advance non-small cell lung cancer . We perform dose escalation pemetrexed determine full dose ( 500mg/m2 ) pemetrexed could administrate concurrently cisplatin conventional dose radiotherapy ( 66Gy ) firstly . Secondly , radiation dose escalate determine maximum tolerate dose ( MTD ) radiotherapy administer concurrently full dose pemetrexed cisplatin .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Age ≧18 year . Performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) Scale . Patients histologically cytologicalproven nonsmall cell lung cancer . Stage IIIA IIIB , exclude pericardial , pleural effusion , contralateral hilar contralateral supraclavicular lymph node . Patients must measurable disease accord RECIST criterion , detectable tumor encompass radiation therapy field . Weight loss ≦ 5 % previous six month . Patient must adequate blood , liver , lung kidney function within requirement study . Female patient childbearing potential must test negative pregnancy time enrollment base serum pregnancy test . Male female patient must agree use reliable method birth control 3 month follow last dose study drug . Patients must sign studyspecific inform consent form prior study entry . Undifferentiated small cell carcinoma , stage . Complete tumor resection , recurrent disease , patient eligible definitive surgery . Stage IV . Age &lt; 18 year . Performance status ≧2 Eastern Cooperative Oncology Group ( ECOG ) Scale . Previous chemotherapy previous biologic response modifier current lung cancer . Patient previously thoracic radiation therapy . Have receive treatment within last 30 day drug receive regulatory approval indication time study entry . Prior concurrent malignancy except nonmelanomatous skin cancer unless diseasefree five year . Serious concomitant disorder would compromise safety patient , compromise patient 's ability complete study , discretion investigator . History significant neurological mental disorder , include seizure dementia . Inability interrupt aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) 2 day , day , 2 day dose pemetrexed . If patient take NSAID ( Cox2 inhibitor include ) salicylate long halflife ( e.g . naproxen , piroxicam , diflusinal , nabumetone , rofecoxib , celecoxib ) take 5 day , day , 2 day dose pemetrexed . Inability unwillingness take folic acid , vitamin B12 supplementation , dexamethasone . Pregnant lactating female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>non-small cell lung cancer</keyword>
</DOC>